UBL7 Antibody

What is UBL7 and why is it significant in research?

UBL7 (Ubiquitin-like 7) is a ubiquitin-like protein with a canonical length of 380 amino acid residues and a molecular mass of 40.5 kDa in humans. It is ubiquitously expressed across numerous tissue types and plays crucial roles in cellular protein homeostasis . Recent research has identified UBL7 as an interferon-stimulated gene (ISG) that functions as a positive regulator of antiviral innate immunity, making it significant for immunological and virological research . Its involvement in K27-linked polyubiquitination processes indicates its importance in post-translational modification studies and cell signaling research .

What are the common synonyms and alternative nomenclature for UBL7?

When searching literature or databases for UBL7-related research, be aware of these alternative identifiers:

• Ubiquitin-like 7 (bone marrow stromal cell-derived)

• Ubiquitin-like protein SB132

• Bone marrow stromal cell ubiquitin-like protein (BMSC-UbP)

• BMSCUBP

• MGC14421

• SB132

• TCBA1

These alternative names are important when performing comprehensive literature searches or when cross-referencing findings across different research databases.

How does UBL7 function in the innate immune response?

UBL7 functions as an immunomodulatory adaptor protein with broad-spectrum antiviral capabilities. Mechanistically, UBL7:

• Is upregulated during RNA virus infection and induced by type I interferons as an ISG

• Enhances innate immune responses by promoting K27-linked polyubiquitination of MAVS (mitochondrial antiviral signaling protein)

• Interacts with TRIM21, an E3 ubiquitin ligase of MAVS

• Promotes the interaction between TRIM21 and MAVS in a dose-dependent manner

• Facilitates the recruitment of TBK1 to enhance IFN signaling

• Creates a positive feedback loop that amplifies antiviral responses

UBL7-deficient mice exhibit increased susceptibility to viral infection due to attenuated antiviral innate immunity, demonstrating its physiological importance in host defense .

Experimental Design and Methodological Considerations

A comprehensive validation approach should include:

• Positive controls: Use tissues or cell lines known to express high levels of UBL7 (ubiquitously expressed, but check expression databases for high-expressing tissues)

• Negative controls: Employ UBL7 knockout/knockdown models or tissues known to have minimal expression

• Peptide competition assays: Pre-incubate antibody with excess UBL7 recombinant protein (such as the PrEST antigen UBL7) to confirm signal specificity

• Cross-reactivity assessment: Test against known UBL7 orthologs if working with non-human models (orthologs reported in mouse, rat, bovine, frog, zebrafish, chimpanzee, and chicken)

• Multiple antibody validation: Compare results using antibodies targeting different epitopes of UBL7

• Protein array testing: Some commercial antibodies have been verified on protein arrays containing target protein plus hundreds of non-specific proteins

This multi-faceted approach ensures reliable and reproducible results when working with UBL7 antibodies.

What sample preparation protocols optimize UBL7 detection in Western blotting?

For optimal UBL7 detection in Western blotting:

• Lysis buffer selection: Use RIPA buffer supplemented with protease inhibitors for general applications; consider NP-40 buffer for co-immunoprecipitation studies investigating UBL7 interactions with TRIM21 or MAVS

• Protein denaturation: Standard heat denaturation (95°C for 5 minutes) in reducing sample buffer is suitable

• Gel percentage: Use 10-12% SDS-PAGE gels for optimal resolution of the 40.5 kDa UBL7 protein

• Transfer conditions: Semi-dry transfer at 15V for 45 minutes or wet transfer at 100V for 1 hour in 10-20% methanol transfer buffer

• Blocking: 5% non-fat milk in TBST for 1 hour at room temperature to reduce background

• Antibody incubation: Dilute primary antibody to 0.04-0.4 μg/mL in 5% BSA or milk and incubate overnight at 4°C

• Detection method: HRP-conjugated secondary antibodies with enhanced chemiluminescence provide sufficient sensitivity for endogenous UBL7 detection

This protocol optimizes the detection of UBL7's molecular weight band at approximately 40.5 kDa and minimizes non-specific background signals.

How can UBL7 antibodies be utilized in studying virus-host interactions?

UBL7 antibodies serve as critical tools for investigating virus-host interactions through several advanced approaches:

• Temporal expression studies: Track UBL7 upregulation during RNA virus infection time courses using Western blotting and IHC

• Subcellular relocalization analysis: Use immunofluorescence to monitor UBL7 localization changes during viral infection

• Protein complex immunoprecipitation: Isolate UBL7 complexes with TRIM21 and MAVS to characterize dynamic changes in these interactions during infection

• Phosphorylation state analysis: Combine UBL7 antibodies with phospho-specific antibodies to assess potential post-translational modifications during immune activation

• ChIP-seq applications: Investigate whether UBL7 associates with chromatin during interferon responses

• In vivo tissue-specific expression: Use IHC to map UBL7 expression in tissues from virus-infected versus healthy animals

These approaches help elucidate the molecular mechanisms by which UBL7 contributes to broad-spectrum antiviral immunity and its potential as a therapeutic target.

What considerations are important when investigating UBL7's role in K27-linked polyubiquitination processes?

When studying UBL7's involvement in K27-linked polyubiquitination:

• Antibody compatibility: Ensure compatibility between UBL7 antibodies and K27-linkage-specific ubiquitin antibodies for co-localization studies

• Ubiquitination assays: Perform in vitro and in vivo ubiquitination assays using UBL7 antibodies for immunoprecipitation, followed by K27-linkage-specific detection

• Conformation-specific considerations: Some epitopes may be masked in protein complexes; test multiple antibodies targeting different regions of UBL7

• Cell treatment conditions: Include proteasome inhibitors (MG132) and deubiquitinase inhibitors (PR-619) in lysis buffers to preserve ubiquitination status

• Controls: Include UBL7-deficient samples and TRIM21 knockdown controls when studying this pathway

• Sequential immunoprecipitation: Consider two-step IP protocols (first for MAVS, then for K27-linked chains) to specifically isolate relevant complexes

This methodological framework enables detailed investigation of how UBL7 specifically promotes K27-linked polyubiquitination in the context of antiviral signaling.

What approaches can resolve contradictory findings regarding UBL7 function in different experimental systems?

To address contradictory results in UBL7 research:

• Cell type specificity: Systematically compare UBL7 function across multiple cell types using the same antibodies and protocols; UBL7 may have tissue-specific roles

• Viral strain differences: Test multiple RNA virus strains to determine if UBL7's effects are virus-specific

• Antibody epitope mapping: Verify whether different antibodies targeting distinct UBL7 epitopes yield consistent results

• Complementary methodologies: Combine antibody-based detection with genetic approaches (CRISPR/Cas9 editing, overexpression)

• Interactome analysis: Use IP-mass spectrometry with UBL7 antibodies to characterize the complete interactome across different experimental conditions

• Model organism validation: Extend studies to multiple model systems (cell lines, primary cells, animal models) using cross-reactive antibodies

This comprehensive approach helps reconcile apparently contradictory findings and establishes a more nuanced understanding of UBL7's context-dependent functions.

What are common artifacts in UBL7 antibody-based assays and how can they be mitigated?

Researchers frequently encounter these artifacts when working with UBL7 antibodies:

• Non-specific bands in Western blots:

  • Mitigation: Increase antibody dilution (0.04-0.4 μg/mL range), use gradient gels for better resolution, include UBL7 knockout/knockdown controls

• Variable staining intensity in IHC:

  • Mitigation: Optimize antigen retrieval methods, standardize fixation times, consider alternative epitope-targeting antibodies, use rat brain or heart tissues as positive controls

• Inconsistent immunoprecipitation efficiency:

  • Mitigation: Test different lysis conditions, adjust antibody:bead ratios, consider using recombinant PrEST antigen as a competitor in negative controls

• Background in immunofluorescence:

  • Mitigation: Increase blocking time/concentration, optimize permeabilization conditions, include an additional washing step with high-salt buffer

• Epitope masking in protein complexes:

  • Mitigation: Test antibodies targeting different UBL7 regions, modify fixation protocols, consider native versus denaturing conditions

These troubleshooting approaches help distinguish genuine UBL7 signals from technical artifacts.

How can researchers evaluate batch-to-batch consistency of UBL7 antibodies?

To ensure reproducible results across different antibody batches:

• Reference sample library: Maintain a set of well-characterized positive control samples (cell lysates or tissue sections) to test each new antibody batch

• Quantitative metrics: Establish acceptance criteria for key parameters:

  • Western blot: Signal-to-noise ratio, band intensity at 40.5 kDa

  • IHC: Staining intensity score, background levels, specificity pattern

  • IP: Pull-down efficiency (% of input)

• Recombinant antigen controls: Use PrEST Antigen UBL7 recombinant protein fragments to verify specific binding

• Validation across applications: Test new batches in multiple applications if the antibody will be used for diverse experiments

• Dilution series comparison: Compare titration curves between batches to identify potential shifts in optimal working concentrations

Implementing these quality control measures ensures consistent performance and facilitates accurate comparison of results across different experimental series.

How might UBL7 antibodies contribute to understanding novel interferon-stimulated gene functions?

UBL7 antibodies can advance interferon biology research through:

• Temporal profiling: Characterize the kinetics of UBL7 upregulation in response to different interferon subtypes and concentrations

• ISG interactome mapping: Use UBL7 antibodies for immunoprecipitation coupled with mass spectrometry to identify novel protein-protein interactions during interferon responses

• Tissue-specific ISG responses: Apply IHC to map differential UBL7 expression across tissues following interferon stimulation

• Single-cell resolution studies: Combine UBL7 antibodies with other ISG markers for multiplex immunofluorescence to characterize cell-specific responses

• Functional clustering analysis: Compare UBL7 expression patterns with other ISGs to identify co-regulated networks

Understanding UBL7's role as an ISG provides insight into the broader orchestration of interferon-mediated antiviral defense mechanisms .

What methods can determine if post-translational modifications regulate UBL7 function?

To investigate potential PTMs regulating UBL7:

• Phosphorylation analysis: Combine UBL7 immunoprecipitation with phospho-specific antibodies or mass spectrometry

• SUMOylation and ubiquitination studies: Use UBL7 antibodies for IP followed by SUMO or ubiquitin detection

• Site-directed mutagenesis validation: Create mutants of predicted modification sites and compare immunoreactivity patterns

• 2D gel electrophoresis: Separate different UBL7 isoforms based on charge modifications

• Antibody specificity testing: Validate whether existing antibodies show differential reactivity to modified forms of UBL7

• Kinase/enzyme inhibitor treatments: Assess changes in UBL7 mobility or immunoreactivity following treatment with inhibitors of specific PTM pathways

These approaches help elucidate how UBL7's antiviral functions might be regulated through post-translational control mechanisms.

How can UBL7 antibody-based approaches contribute to therapeutic development strategies?

UBL7 antibodies can facilitate therapeutic research through:

• Target validation studies: Use antibodies to confirm UBL7 expression in relevant disease models and patient samples

• High-throughput screening support: Develop UBL7-based assays for identifying compounds that modulate its antiviral activities

• Mechanism of action studies: Apply antibodies to characterize how candidate therapeutics affect UBL7 expression, localization, or interactions

• Biomarker development: Explore UBL7 expression patterns as potential biomarkers for interferon responsiveness

• Animal model validation: Use cross-reactive antibodies to translate findings between preclinical models and human studies

• Tissue-specific delivery assessment: Monitor UBL7 pathway activation in target tissues following experimental therapeutic interventions